Physician Perspectives 2017: Use of ustekinumab in IBD
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› Questions topics:
– Current clinical use of UST
– UST safety & efficacy
– UST patient monitoring
– Treatment response to UST
– UST treatment strategies›Future use in UC
Scope
Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
Physicians interviewed were from 5EU and US countries
This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics
Key Highlights
UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn’s disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ
73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met
Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI
Reasons to Buy
Qualitative insight from 100 high-prescribing specialists in IBD
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Takeda
AbbVie
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.